Sanofi and Regeneron’s immunology blockbuster Dupixent had been on a mini streak as king of the pharma airwaves but was knocked off its perch in June by AbbVie’s competing drug Rinvoq. That’s ...
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...
Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a ...
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...
Dupixent is used to help treat certain inflammatory conditions, including atopic dermatitis and asthma, in adults and some children. This medication comes in prefilled syringes and prefilled pens for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback